Partner Headlines - EXEL

  1. Events for the Week of Nov. 17-21, 2014

    Benzinga
  2. Morning Market Movers

    Benzinga
  3. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  4. Stocks Hitting 52-Week Lows

    Benzinga
  5. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  6. Midday Losers From Tuesday, September 2

    Benzinga
  7. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  8. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  9. Stocks Hitting 52-Week Lows

    Benzinga
  10. Morning Market Losers

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  13. Stocks To Watch For September 2, 2014

    Benzinga
  14. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  15. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  16. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  17. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  18. Morning Market Movers

    Benzinga
  19. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  20. Benzinga's Top #PreMarket Gainers

    Benzinga
  21. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  24. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  25. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  26. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  27. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  28. Stocks Hitting 52-Week Lows

    Benzinga
  29. Morning Market Losers

    Benzinga
  30. Benzinga's Top #PreMarket Losers

    Benzinga
  31. Morning Market Movers

    Benzinga
  32. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  33. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  34. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  35. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  36. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  37. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  38. US Stock Futures Up After Upbeat China Data

    Benzinga
  39. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  40. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  41. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  42. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  43. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  44. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  45. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  46. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  47. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  48. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  49. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  50. Health Care Sector Wrap

    FoxBusiness
  51. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  52. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  53. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  54. Exelixis Proposed Offering 20M Shares

    Benzinga
  55. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  56. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  57. Benzinga's Top Pre-Market Gainers

    Benzinga
  58. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  59. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  60. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  61. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  62. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  63. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  64. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  65. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  66. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  67. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  68. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  69. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  70. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  71. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  72. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  73. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  74. Notable Call Options Activity on Exelixis

    Benzinga
  75. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  76. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center